Asset
Ivonescimab
Summit Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06396065 | phase3 | active_not_recruiting | 2023-05-04 | 2025-04-12 | Summit Therapeutics | Phase III Study of AK112 for NSCLC Patients |
FDA applications (0)
This company has no applications containing this asset.